Stockscreener 앱 받기
7.33
0.96%
0.07
시간 외 거래:
7.33
전일 마감가:
$7.26
열려 있는:
$7.36
하루 거래량:
634.63K
Relative Volume:
0.78
시가총액:
$378.20M
수익:
$676.80M
순이익/손실:
$-8.60M
주가수익비율:
-25.91
EPS:
-0.2829
순현금흐름:
$135.40M
1주 성능:
-4.68%
1개월 성능:
-14.07%
6개월 성능:
-40.02%
1년 성능:
+2.23%
1일 변동 폭
$7.2928
$7.50
1주일 범위
$7.235
$7.73
52주 변동 폭
$5.615
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
7.33 | 374.59M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Emergent BioSolutions Inc (EBS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
EBS|Emergent BioSolutions Inc|Price:7.260| - TradingKey
EBS|Emergent BioSolutions Inc|Price:7.260|Chg%:-0.240 - TradingKey
EBS5025997 Bond Risk Profile - TradingView
EBS5025997 Bond Profile — Key Metrics - TradingView
Emergent BioSolutions Inc (EBS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Emergent BioSolutions to report Q2 2026 results on August 5 - scanx.trade
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Emergent BioSolutions offers live webcast for Aug. 5 results call - Stock Titan
Emergent BioSolutions (EBS) AGM 2026 Summary - Quartr
Emergent BioSolutions (EBS) Q3 2024 earnings summary - Quartr
Emergent BioSolutions (EBS) Proxy filing Summary - Quartr
Emergent BioSolutions (EBS) Q1 2026 earnings summary - Quartr
Lobbying Update: $510,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Quiver Quantitative
EBS5025998 Bond Profile — Key Metrics - TradingView
EBS5025998 Bond Coupon Profile — Rate & Payments - TradingView
Price to sales forward of Emergent BioSolutions Inc. – LS:A0LC2W - TradingView
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Mutual of America Capital Management LLC - 富途牛牛
Emergent BioSolutions Company Profile & Introduction - Moomoo
Emergent BioSolutions highlights its role in specialty vaccines as investors weigh the long-term out - Ad-hoc-news.de
Insider Sell: Paul Williams Sells 3,000 Shares of Emergent BioSo - GuruFocus
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
Emergent BioSolutions SVP Williams sells $25,200 in common stock By Investing.com - Investing.com Nigeria
Emergent BioSolutions SVP Williams sells $25,200 in common stock - Investing.com
Form 4 Emergent Biosolutions Inc For: 2 July By Investing.com - Investing.com Canada
Emergent BioSolutions (EBS) SVP sells 3,000 shares under plan - Stock Titan
Emergent BioSolutions | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] Emergent BioSolutions Inc. SEC Filing - Stock Titan
Emergent BioSolutions Secures Contract Modification Valued At Approximately USD 52.7 Million From The United States Department Of Health And Human Services To Supply ACAM2000 - marketscreener.com
Emergent BioSolutions Secures New ACAM2000 Biodefense Contract - TipRanks
Emergent BioSolutions (NYSE: EBS) lands $52.7M U.S. ACAM2000 contract - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Emergent BioSolutions (EBS) Secures $52.7M Contract for Smallpox Vaccine Supply - GuruFocus
Emergent BioSolutions wins $52.7m smallpox vaccine contract By Investing.com - Investing.com South Africa
Emergent BioSolutions wins $52.7m smallpox vaccine contract - Investing.com
U.S. government adds $52.7M ACAM2000 order for smallpox preparedness - Stock Titan
Emergent BioSolutions Inc. Actuals & Estimates (NYSE:EBS) - TradingView
Emergent BioSolutions | 8-K: Current report - Moomoo
Emergent BioSolutions Inc. Actuals & Estimates (BOATS:EBS) - TradingView
EBS Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Emergent BioSolutions Inc. – NYSE:EBS - TradingView
Enterprise value to revenue forward of Emergent BioSolutions Inc. – BOATS:EBS - TradingView
Price to sales forward of Emergent BioSolutions Inc. – NYSE:EBS - TradingView
Emergent Biosolutions studies intranasal naloxone for opioid overdose response - Traders Union
Emergent BioSolutions Inc (EBS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Emergent BioSolutions StockSunday background on the business and risk profile - AD HOC NEWS
Why Emergent’s Narcan nasal spray is becoming a quiet everyday life saver - Ad-hoc-news.de
Emergent BioSolutions Inc (EBS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
2.01%
자본화:
|
볼륨(24시간):